- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03880253
Multiple Ascending Dose Study of CTP-692 in Healthy Volunteers
June 12, 2019 updated by: Concert Pharmaceuticals
A Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety and Pharmacokinetic Profile of CTP-692 in Healthy Volunteers
This study will assess in healthy male and female subjects the safety and pharmacokinetic (PK) profiles of 3 dose levels of CTP-692 following 7 days of dosing.
Study Overview
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Long Beach, California, United States, 90806
- Collaborative Neuroscience Network, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult males and females between 18 and 55 years of age, inclusive
- Body weight ≥ 55 kg and body mass index within the range of 18 to 32 kg/m2, inclusive
Exclusion Criteria:
- Screening laboratory measurements outside the normal range associated with potential risk for the treatment under investigation at screening and/or prior to the first dose of study drug
- Positive blood screen for human immunodeficiency virus (HIV antibody), hepatitis B virus surface antigen or hepatitis C virus antibody
- History of clinically significant central nervous system (e.g., seizures), cardiac, pulmonary, metabolic, renal, hepatic or gastrointestinal (GI) conditions
- Positive drug or alcohol test at screening or prior to the first dose of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CTP-692 Low Dose or Matching Placebo
Once daily dosing
|
Placebo or CTP-692
|
Experimental: CTP-692 Mid Dose or Matching Placebo
Once daily dosing
|
Placebo or CTP-692
|
Experimental: CTP-692 High Dose or Matching Placebo
Once daily dosing
|
Placebo or CTP-692
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of participants with adverse events as a measure of safety
Time Frame: Assessments done Day 1 - 9
|
Assessments done Day 1 - 9
|
Measurement of CTP-692 exposure in plasma
Time Frame: Assessments done Day 1 - 9
|
Assessments done Day 1 - 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 10, 2019
Primary Completion (Actual)
May 16, 2019
Study Completion (Actual)
May 16, 2019
Study Registration Dates
First Submitted
March 15, 2019
First Submitted That Met QC Criteria
March 15, 2019
First Posted (Actual)
March 19, 2019
Study Record Updates
Last Update Posted (Actual)
June 13, 2019
Last Update Submitted That Met QC Criteria
June 12, 2019
Last Verified
June 1, 2019
More Information
Terms related to this study
Other Study ID Numbers
- CP692.1003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on CTP-692
-
Concert PharmaceuticalsCompletedHealthyUnited States
-
Concert PharmaceuticalsCognitive Research CorporationCompleted
-
Concert PharmaceuticalsCompletedHealthy VolunteersAustralia
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States, Canada
-
Concert PharmaceuticalsCompleted
-
Concert PharmaceuticalsCompleted
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States
-
Concert PharmaceuticalsCompletedAlopecia AreataUnited States
-
Concert PharmaceuticalsCompleted
-
Concert PharmaceuticalsCompletedHepatic ImpairmentUnited States